NFE4 (Gene)

Omim:OMIM:612133

Id:4537f2bf-c0f5-51cc-afc6-0e9f25a27490

Hgnc:HGNC:29902

Entrez:58160

Description:nuclear factor, erythroid 4

The erythroid-specific protein encoded by this gene, and the ubiquitous transcription factor CP2, form the stage selector protein (SSP) complex, which is involved in preferential expression of the gamma-globin genes in fetal erythroid cells. Alternate use of an in-frame upstream non-AUG (CUG) translation initiation codon, and a downstream AUG codon, results in two isoforms. While the long isoform (22 kDa) acts as an activator, the short isoform (14 kDa) has been shown to repress gamma-globin gene expression. This gene is located in an intron of the FBXL13 gene on the opposite strand. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NFE4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NFE4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NFE4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NFE4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NFE4.

Results found

Linked to

	Label	Description
	GSE108464 AZ-628 1 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 6 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 trametinib YAP 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE201309 matrine 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE108464 AZ-628 1 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 6 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE130401 trametinib YAP 6 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE201309 matrine 1 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.